NCT05236855View on ClinicalTrials.gov

Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening

UnknownOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 1, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions
Cervical CancerHPV
Interventions
DIAGNOSTIC_TEST

Spectoscropy testing of urine specimen

Urine samples will be independently tested by I R Spectroscopy and those results are to be compared with standard testing procedures for HPV

Sponsors

Lead Sponsor

IWK Health Centre
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Canadian Cancer Society (CCS)

OTHER

collaborator

Lancaster University

OTHER

collaborator

Nova Scotia Health Authority

OTHER

lead

IWK Health Centre

OTHER

NCT05236855 - Spectroscopy and Artificial Intelligence to Disrupt the Status Quo in Cervical Cancer Screening | Biotech Hunter | Biotech Hunter